Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | KLK1 | P06870 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2782337 | 0.96 | F10 (0.48) | F10NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2779558 | 0.94 | F10 (0.49) | F10NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2781719 | 0.92 | F10 (0.48) | F10NPC1RAB9AF2PLAT | |
| SCHEMBL2782382 | 0.92 | F10 (0.48) | F10NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2781726 | 0.91 | F10 (0.46) | F10NPC1RAB9AF2PLAT | |
| SCHEMBL2782297 | 0.90 | F10 (0.47) | F10NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2783613 | 0.89 | F10 (0.49) | F10F2PLATKLK1 | |
| SCHEMBL2782300 | 0.88 | F10 (0.46) | F10F2PLATKLK1 | |
| SCHEMBL1456862 | 0.88 | F10 (0.49) | F10F2 | |
| SCHEMBL2779827 | 0.87 | F10 (0.45) | F10F2PLATKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010045-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-01-14 | — | — | US | claimed |
| EP-1581523-B1 | PYRAZOLE-DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-09-30 | — | — | EP | claimed |
| US-20080306056-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| EP-1581523-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2005-10-05 | — | — | EP | claimed |
| EP-1479678-A1 | Pyrazole-derivatives as factor xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | claimed |
| US-20040204406-A1 | Pyrazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-14 | — | — | US | claimed |
| WO-2004056815-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | WO | claimed |
| EP-1433788-A1 | Pyrazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-06-30 | — | — | EP | claimed |
| US-20100010045-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| EP-1581523-B1 | PYRAZOLE-DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-20080306056-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-7429581-B2 | Pyrazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-09-30 | — | — | US | disclosed |
| EP-1581523-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1479678-A1 | Pyrazole-derivatives as factor xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
| US-20040204406-A1 | Pyrazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-14 | — | — | US | disclosed |
| WO-2004056815-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | WO | disclosed |
| EP-1433788-A1 | Pyrazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306056-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | F12, F5, F11 | F10 10/4885NPC1 3683/4885RAB9A 774/4885 |
| US-20040204406-A1 | Pyrazole-derivatives as factor Xa inhibitors | F11, F5, F12 | F10 11/4885NPC1 3705/4885RAB9A 540/4885 |
| US-20100010045-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | F12, F5, F11 | F10 10/4885NPC1 4204/4885RAB9A 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.